Artivion Inc (Artivion), formerly CyroLife, is a biomaterial and biosurgical device company. It manufactures, processes, and distributes implantable human tissues for use in cardiac and vascular surgical applications in patients with aortic disease. The company’s offerings include vascular allografts, preserved human cardiac allografts, heart valves, surgical adhesives and sealants, bovine pericardium, and mitral chordal repair products. The company operates through two reportable business segments: Medical Devices and Preservation Services. The company manufactures BioFoam, BioGlue, and PerClot, and processes tissues at its facility in Atlanta, Georgia, the US. The company operates On-X facility in Austin, Texas, the US. It has laboratory space for CardioGenesis cardiac laser therapy maintenance and evaluation purpose. It also has Jotec facility consists of manufacturing, warehousing, and office space in Hechingen, Germany. The company has a facility consisting of manufacturing, warehousing, and office space leased in Austin, Texas. It also has manufacturing and office space leased in Atlanta, Georgia.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Artivion's research and development (R&D) activities concentrate on the preservation of human cardiac and vascular cells and tissues, and the development of surgical adhesives that enable cardiac and vascular surgeons to repair and reconstruct complex cardiac and vascular anomalies. Its facilities are ISO 13485 certified. In FY2022, the company’s spent US$38.9 on R&D activities, which accounted for 12.4% of the company’s revenue.